Publications by authors named "M J Vekemans"
Article Synopsis
- The IMWG frailty index shows that frailty levels in patients undergoing anti-myeloma treatment can change frequently over time.
- Assessing frailty dynamically during treatment provides better predictions for survival and early mortality than just looking at initial frailty levels.
- The study references two clinical trials, HOVON 143 (NTR6297) and HOVON 123 (NTR4244), related to this research.
Article Synopsis
- MRI is effective at identifying bone marrow involvement in multiple myeloma but struggles with detecting bone lesions, prompting a study to test new MRI techniques (ZTE and BB) against whole-body CT as a reference.
- The study included 47 patients diagnosed with multiple myeloma or at high risk, assessing the performance of ZTE and BB MRI sequences alongside PET/CT scans for detecting osteolytic lesions.
- Results showed that experienced radiologists achieved high accuracy (98%) with both MRI techniques, but there were noticeable discrepancies in detection rates across different regions, particularly with an increased false-negative rate in the spine when using ZTE.
Article Synopsis
- - The study focuses on older patients (over 60 years) with acute myeloid leukemia (AML) and aims to create a prognostic model to identify those who would benefit from intensive chemotherapy and stem cell transplantation.
- - Researchers analyzed data from 1,910 patients, using a random survival forest to evaluate clinical and genetic factors associated with overall survival, resulting in the identification of four distinct survival groups based on nine variables.
- - The newly developed AML60+ classification shows improved prognostic accuracy and indicates that intermediate- and very poor-risk patients may benefit from allogeneic hematopoietic cell transplantation, potentially guiding treatment decisions for older adults with AML.
Background: CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone as an induction and consolidation regimen in transplant-eligible patients newly diagnosed with myeloma. In CASSIOPEIA part 2, daratumumab maintenance significantly improved progression-free survival and increased minimal residual disease (MRD)-negativity rates versus observation. Here, we report long-term study outcomes of CASSIOPEIA.
View Article and Find Full Text PDFPurpose: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM).
Methods: Phase II eligible patients had RRMM that either progressed on/after ≥three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI/IMiD/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks.